Reproducibility and expression of skin biomarkers in sun-damaged skin and actinic keratoses

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 10, 2006, Pages 1841-1848

  Einspahr, Janine G ^a,c   Xu, Min Jian ^a   Warneke, James ^a   Saboda, Kathylynn ^b   Ranger Moore, James ^b   Bozzo, Paul ^a   Duckett, Laura ^b   Goldman, Rayna ^b   Lin, Po ^b   Buckmeier, Julie ^b   Alberts, David S ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLINE; POLYAMINE; PROTEIN P53; PUTRESCINE; SPERMIDINE; SUNSCREEN;

ACTINIC KERATOSIS; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION CARCINOGENESIS; REPRODUCIBILITY; SKIN BIOPSY; SKIN CANCER; SKIN DEFECT; SQUAMOUS CELL; SUN EXPOSURE; ULTRAVIOLET RADIATION;

ADULT; AGED; BIOGENIC POLYAMINES; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; FEMALE; FOREARM; HUMANS; IMMUNOHISTOCHEMISTRY; KERATOSIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, RADIATION-INDUCED; PRECANCEROUS CONDITIONS; PROLIFERATING CELL NUCLEAR ANTIGEN; REPRODUCIBILITY OF RESULTS; SKIN NEOPLASMS; SUNSCREENING AGENTS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 33750518575     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0378     Document Type: Article

References (50)

1. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;294:1255-9.
2. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002; 146 Suppl 61:1-6.
3. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000;42:S4-7.
4. Marks R, Remue G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988;1:795-7.
5. Fritzgerald DA. Cancer precursors. Semin Cutan Med Surg 1998;17:108-13.
6. Marks R. Solar keratoses. Br J Dermatol 1990;122 Suppl 35:49-54.
7. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). J Am Acad Dermatol 2000;42:11-7.
8. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A 1991;88:10124-8.
9. Campbell C, Quinn AG, Ro YS, Angus B, Rees JL. p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin. J Invest Dermatol 1993;100:746-8.
10. Kubo Y, Urano Y, Yoshimoto K, et al. p53 gene mutations in human skin cancers and precancerous lesions: comparison with immunohistochemical analysis. J Invest Dermatol 1994;102:440-4.
11. Moles JP, Moyret C, Guillot B, et al. p53 gene mutations in human epithelial skin cancers. Oncogene 1993;8:583-8.
12. Nelson MA, Einspahr JG, Alberts DS, et al. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett 1994;85:23-9.
13. Taguchi M, Watanabe S, Yashima K, Murakami Y, Sekiya T, Ikeda S. Aberrations of the tumor suppressor p53 gene and p53 protein in solar keratosis in human skin. J Invest Dermatol 1994;103:500-3.
14. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994;372:773-6.
15. Leffell DJ. The scientific basis of skin cancer. J Am Acad Dermatol 2000;42:18-22.
16. Nataraj AJ, Trent JC II, Ananthaswamy HN. p53 gene mutations and photocarcinogenesis. Photochem Photobiol 1995;62:218-30.
17. Greenwald P. Cancer chemoprevention. BMJ 2002;324:714-8.
18. Boone CW, Kelloff GJ, Steele VE. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res 1992;52:1651-9.
19. Anwar J, Wrone DA, Kimyai-Asadi A, Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol 2004;22:189-96.
20. Carpenter PM, Linden KG, McLaren CE, et al. Nuclear morphometry and molecular biomarkers of actinic keratosis, sun-damaged, and nonexposed skin. Cancer Epidemiol Biomarkers Prev 2004;13:1996-2002.
21. Einspahr J, Alberts DS, Aickin M, et al. Expression of p53 protein in actinie keratosis, adjacent, normal-appearing, and non-sun-exposed human skin. Cancer Epidemiol Biomarkers Prev 1997;6:583-7.
22. Einspahr JG, Alberts DS, Warneke JA, et al. Relationship of p53 mutations to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesis. Neoplasia 1999;1:468-75.
23. Jonason AS, Kurtala S, Price GJ, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci U S A 1996;93:14025-9.
24. McNutt NS, Saenz-Santamaria C, Volkenandt M, Shea CR, Albino AP. Abnormalties of p53 protein expression in cutaneous disorders. Arch Dermatol 1991;130:225-32.
25. Ren ZP, Hedrum A, Ponten F, et al. Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes. Oncogene 1996;12:765-73.
26. Ro YS, Cooper PN, Lee JA, et al. p53 protein expression in benign and malignant skin tumours. Br J Dermatol 1993;128:237-41.
27. Shea CR, McNutt NS, Volkenandt M, Lugo J, Prioleau PG, Albino AP. Overexpression of p53 protein in basal cell carcinomas of human skin. Am J Pathol 1992;141:25-9.
28. Sim CS, Slater SD, McKee PH. Mutant p53 protein is expression in solar keratosis: an immunohistochemical study. J Cutan Pathol 1991;19:302-8.
29. Sim CS, Slater SD, McKee PH. Mutant p53 protein is expressed in Bowen's disease. Am J Dermatopathol 1992;14:195-9.
30. Urano Y, Asano T, Yoshimoto K, et al. Frequent p53 accumulation in the chronically sun-exposed epidermis and clonal expansion of p53 mutant cells in the epidermis adjacent to basal cell carcinoma. J Invest Dermatol 1995;104:928-32.
31. Urano Y, Oura H, Sakaki A, et al. Immunohistological analysis of P53 expression in human skin tumors. J Dermatol Sci 1992;4:69-75.
32. Einspahr JG, Nelson MA, Saboda K, Warneke J, Bowden GT, Alberts DS. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer. Clin Cancer Res 2002;8:149-55.
33. van der Pols JC, Xu C, Boyle GM, Parsons PG, Williams GM, Green AC. Is expression of p53 protein in dorsal hand predictive of the seven year risk and site distribution of basal and squamouns cell carcinomas of the skin? In: AACR, editor. Frontiers in cancer prevention; 2005 October 30 to November 2. Baltimore (Maryland): AACR; 2005. p. A16.
34. Young AR. Aspects of psoralen phototumorigenesis with emphasis on the possible role of tumour promotion. Biochimie 1986;68:885-9.
35. Seiler N, Knodgen B. Effects of ultraviolet light on epidermal polyamine metabolism. Biochem Med 1979;21:168-81.
36. Lowe NJ. Ultraviolet light and epidermal polyamines. J Invest Dermatol 1981;77:147-53.
37. Basuroy UK, Gerner EW. Emerging concepts in targeting the polyamine metabolic pathway in epithelial cancer chemoprevention and chemotherapy. J Biochem (Tokyo) 2006;139:27-33.
38. Khettab N, Amory MC, Briand G, et al. Photoprotective effect of vitamins A and E on polyamine and oxygenated free radical metabolism in hairless mouse epidermis. Biochimie 1988;70:1709-13.
39. O'Brien TG, Megosh LC, Gilliard G, Soler AP. Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin. Cancer Res 1997;57:2630-7.
40. Peralta Soler A, Gilliard G, Megosh L, George K, O'Brien TG. Polyamines regulate expression of the neoplastic phenotype in mouse skin. Cancer Res 1998;58:1654-9.
41. Hietala O, Dzubow L, Dlugosz AA, et al. Activation of human squamous cell carcinoma ornithine decarboxylase activity by guanosine triphosphate. Cancer Res 1988;48:1252-7.
42. Scalabrino G, Pigatto P, Ferioli ME, Modena D, Puerari M, Caru A. Levels of activity of the polyamine biosynthetic decarboxylases as indicators of degree of malignancy of human cutaneous epitheliomas. J Invest Dermatol 1980;74:122-4.
43. Kagoura M, Toyoda M, Matsui C, Morohashi M. Immunohistochemical localization of ornithine decarboxylase in skin tumors. J Cutan Pathol 2000; 27:338-43.
44. Einspahr J, Alberts DS, Aickin M, et al. Evaluation of proliferating cell nuclear antigen as a surrogate end point biomarker in actinic keratosis and adjacent, normal-appearing, and non-sun-exposed human skin samples. Cancer Epidemiol Biomarkers Prev 1996;5:343-8.
45. Kerr C. The effects of two UVB radiation-absorbing sunscreens on UV radiation-induced carcinogenesis, suppression of the contact hypersensitivity response and histological changes in the hairless mouse. Mutat Res 1998; 422:161-4.
46. Kligman LH, Akin FJ, Kligman AM. Sunscreens prevent ultraviolet photocarcinogenesis. J Am Acad Dermatol 1980;3:30-5.
47. Ananthaswamy HN, Ullrich SE, Mascotto RE, et al. Inhibition of solar simulator-induced p53 mutations and protection against skin cancer development in mice by sunscreens. J Invest Dermatol 1999;112:763-8.
48. Alberts DS, Dorr RT, Einspahr JG, et al. Chemoprevention of human actinic keratoses by topical 2-(dinuoromethyl)-DL-ornithine. Cancer Epidemiol Biomarkers Prev 2000;9:1281-6.
49. Linden KG, Carpenter PM, McLaren CE, et al. Chemoprevention of nonmelanoma skin cancer: experience with a polyphenol from green tea. Recent Results Cancer Res 2003;163:165-71; discussion 264-6.
50. Alberts D, Ranger-Moore J, Einspahr J, et al. Safety and efficacy of dose-intensive oral vitamin A in subjects with sun-damaged skin. Clin Cancer Res 2004;10:1875-80.